Evaluating 3 Types of Targeted Therapies for Triple-Negative Breast Cancer

Aditya Bardia, MBBS, MPH, a breast medical oncologist at Massachusetts General Hospital and Harvard Medical School, discusses the development of targeted therapies for patients with triple-negative breast cancer (TNBC). He says these approaches can be divided into 3 different categories.

The first category would be targeting oncogenes. An example of this would be the use of PARP inhibitors. Second, ongoing trials are also looking at intercellular signaling pathways, says Bardia.